Oak Hill Bio

Oak Hill Bio

HealthRare Disease Therapeutics📍 United States

Oak Hill Bio is a therapeutics company focused on developing treatments for rare diseases. They have secured funding to advance rugonersen, an experimental treatment for Angelman syndrome, into late-stage clinical testing, highlighting their commitment to addressing unmet medical needs in this community.

Total raised
$32.5M
tracked to date
Latest round
$32.5M
Jun 8, 2026

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. 1
    $32.5MJun 8, 2026
    Announcement ↗

Founder

Josh Distler
Josh Distler
CEO

Oak Hill Bio in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile